A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans Gerhard Nahler, Franjo Grotenhermen, Antonio Waldo Zuardi, and Jose´ A.S. Crippa3 Cannabis and Cannabinoid Research, 2017, 2, 1, 81-86 DOI: 10.1089/can.2017.0009 Abstract Cannabidiol (CBD), a major cannabinoid of hemp, does not bind to CB1 receptors and is therefore devoid of psychotomimetic properties. Under acidic conditions, CBD can be transformed to delta9 tetrahydro-cannabinol (THC) and other cannabinoids. It has been argued that this may occur also after oral administration in humans. However, the experimental conversion of CBD to THC and delta8-THC in simulated gastric fluid (SGF) is a highly artificial approach that deviates [...]
Lire la suiteIdentification of Terpenoid Chemotypes Among High (-)-trans-D9- Tetrahydrocannabinol-Producing Cannabis sativa L. Cultivars Justin T. Fischedick Cannabis and Cannabinoid Research, 2017, 2, 1, 34-47 DOI: 10.1089/can.2016.0040 Abstract Introduction : With laws changing around the world regarding the legal status of Cannabis sativa (cannabis) it is important to develop objective classification systems that help explain the chemical variation found among various cultivars. Currently cannabis cultivars are named using obscure and inconsistent nomenclature. Terpenoids, responsible for the aroma of cannabis, are a useful group of compounds for distinguishing cannabis cultivars with similar cannabinoid content. Methods : In this study we analyzed terpenoid content of cannabis samples obtained from a [...]
Lire la suiteLe cannabis à visée thérapeutique : travaux du CSST et de l’ANSM Projet de cadre de la phase expérimentale Direction des médicaments de neurologie-psychiatrie-antalgie-stupéfiants Nathalie Richard Respadd 21 juin 2019 Le cannabis à visée thérapeutique : travaux du CSST et de l’ANSM Nathalie Richard Directrice adjointe ANSM Nathalie RICHARD rappelle que toutes les opérations qui concernent le cannabis sont interdites en France – la production, la détention, l’acquisition et l’utilisation. Des dérogations sont cependant possibles. La première dérogation est liée à une utilisation du cannabis à des fins de recherches. Ainsi, les essais thérapeutiques avec le cannabis possibles en France, sur dérogation du Directeur Général de l’ANSM. L’utilisation de [...]
Lire la suiteUTILISATION DU DRONABINOL (MARINOL ®) EN FRANCE Dr Sarah Lejczak AH, CETD, CHU Nantes sarah.lejczak@chu-nantes.fr 20.06.2019 Utilisation du Marinol en France : enquête auprès des prescripteurs Sarah Lejczak CHU de Nantes Sarah Lejczak, médecin algologue, rappelle qu’il est possible de prescrire du Marinol depuis 2006. Le premier essai clinique sur le cannabis thérapeutique a été réalisé au XIXe siècle, avec des patients atteints de choléra et de tétanos. Ces essais ont été suivis de dérives et de périodes de prohibition. Fort heureusement, des équipes de chercheurs se sont de nouveau emparées de ce sujet à partir des années 1970. Aux États-Unis, l’approche de ce sujet diverge selon les États. [...]
Lire la suiteNovel insights into mitochondrial molecular targets of iron-inducedneurodegeneration: Reversal by cannabidiol Vanessa Kappel da Silva, Betânia Souza de Freitas, Victória Campos Dornelles,Luiza Wilges Kist, Maurício Reis Bogoc, Milena Carvalho Silvad, Emílio Luiz Streck, Jaime Eduardo Hallak, Antônio Waldo Zuardib,e, José Alexandre S. Crippab,e,Nadja Schrödera Brain Research Bulletin, 2018, 139, 1–8 https://doi.org/10.1016/j.brainresbull.2018.01.014 ABSTRACT Evidence has demonstrated iron accumulation in specific brain regions of patients suffering from neurodegen-erative disorders, and this metal has been recognized as a contributing factor for neurodegeneration. Using anexperimental model of brain iron accumulation, we have shown that iron induces severe memory deficits thatare accompanied by oxidative stress, increased apoptotic markers, and decreased [...]
Lire la suiteCannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis : A role for A2A receptors M. Mecha, A. Feliú, P.M. Iñigo, L. Mestre, F.J. Carrillo-Salinas, C. Guaza Neurobiology of Disease, 2013, 59, 141–150 https://doi.org/10.1016/j.nbd.2013.06.016 Inflammation in the central nervous system (CNS) is a complex process that involves a multitude of mole-cules and effectors, and it requires the transmigration of blood leukocytes across the blood–brain barrier(BBB) and the activation of resident immune cells. Cannabidiol (CBD), a non-psychotropic cannabinoid constituent of Cannabis sativa, has potent anti-inflammatory and immunosuppressive properties. Yet, how this compound modifies the deleterious effects of [...]
Lire la suiteCannabis sativa : The Plant of the Thousand and One Molecules Christelle M. Andre, Jean-Francois Hausman and Gea Guerriero Frontiers in Plant Science, 2016, Volume 7, Article 19. doi:10.3389/fpls.2016.00019 Cannabis sativa L. is an important herbaceous species originating from Central Asia, which has been used in folk medicine and as a source of textile fiber since the dawn of times. This fast-growing plant has recently seen a resurgence of interest because of its multi-purpose applications : it is indeed a treasure trove of phytochemicals and a rich source of both cellulosic and woody fibers. Equally highly interested in this plant are the pharmaceutical and [...]
Lire la suiteThe diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids : D9-tetrahydrocannabinol, cannabidiol and D9-tetrahydrocannabivarin Roger G. Pertwee British Journal of Pharmacology, 2008, 153, 199–215 doi:10.1038/sj.bjp.0707442 Cannabis sativa is the source of a unique set of compounds known collectively as plant cannabinoids or phytocannabinoids. This review focuses on the manner with which three of these compounds, (-)-trans-D9-tetrahydrocannabinol (D9-THC), (-)- cannabidiol (CBD) and (-)-trans-D9-tetrahydrocannabivarin (D9-THCV), interact with cannabinoid CB1 and CB2 receptors. D9-THC, the main psychotropic constituent of cannabis, is a CB1 and CB2 receptor partial agonist and in line with classical pharmacology, the responses it elicits appear to be strongly influenced both by [...]
Lire la suiteCannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence Cathrin Rohleder, Juliane K. Müller, Bettina Lange and F. M. Leweke Frontiers in Pharmacology, 2016, Volume 7, Article 422. doi: 10.3389/fphar.2016.00422 There is urgent need for the development of mechanistically different and less side-effect prone antipsychotic compounds. The endocannabinoid system has been suggested to represent a potential new target in this indication. While the chronic use of cannabis itself has been considered a risk factor contributing to the development of schizophrenia, triggered by the phytocannabinoid delta-9-tetra-hydro-cannabinol (19-THC), cannabidiol, the second most important phytocannabinoid, appears to have no psychotomimetic potential. [...]
Lire la suiteLong-lasting analgesic effect of the psychedelic drug changa : A case report Genis ONA and Sebastian TRONCOSO Journal of Psychedelic Studies, 2019, 3, (1), 7–13. DOI: 10.1556/2054.2019.001 Background and aims : Pain is the most prevalent symptom of a health condition, and it is inappropriately treated in many cases. Here, we present a case report in which we observe a long-lasting analgesic effect produced by changa, a psychedelic drug that contains the psychoactive N,N-dimethyltryptamine and ground seeds of Peganum harmala, which are rich in β-carbolines. Methods : We describe the case and offer a brief review of supportive findings. Results : A long-lasting analgesic effect after [...]
Lire la suite